Welcome to the November
Newsletter! As winter approaches, we remain committed to advancing
disease modeling with market-leading iPSC-derived cells. November has
been a month of remarkable progress and engagement.
We celebrated
exciting news from
the UK government that reinforces the importance of innovation in life
sciences. Our team attended SCS Formulate in Coventry, connecting with
experts in the cosmetics and personal care industry, and proudly
exhibited at SfN, where we showcased our neuroscience solutions to
researchers from around the world. We launched a wealth of high-quality
Huntington’s disease content, including whitepapers, eBooks, and
posters, designed to support your research.
Continue reading to discover the exciting developments that have kept
us moving forward throughout November and to
learn about upcoming opportunities to connect with our experts.
Key highlights in November:
- A major milestone for
UK science and innovation
- Key takeaways from SfN
2025
- New whitepaper:
Modeling the genomic instability of Huntington’s disease with iPSC
technology
- New eBook: Human
iPSC-derived cells and specialist services for Huntington’s
disease
- We’ll be at the 36th
International Symposium on ALS/MND, San Diego, 5–7 December
- Planning your last
round of microglia experiments for 2025? Our cells are ready
- Where you can meet the
Axol team!
|
|
|
A major
milestone for UK science and innovation
|
|
|
|
|
Lord Vallance announced the UK Roadmap to Reduce Animal
Testing in Drug Development, a bold step toward accelerating the
adoption of human-relevant research models.
At Axol Bioscience, this roadmap aligns perfectly with
our mission. For over a decade, we’ve been pioneering human
iPSC-derived cells and advanced
in vitro systems to empower researchers to generate
physiologically-relevant and reproducible data, exactly the kind of
innovation this roadmap champions.
|
|
|
Key takeaways
from SfN 2025
|
|
|
|
|
We enjoyed inspiring lectures and poster sessions,
engaging conversations at our booth, and presenting our own poster.
It’s been a science-rich week at SfN in San Diego.
- Alzheimer’s: Hope for early biomarker-guided treatment
with new drugs.
- Organoids: Rising as key disease models.
- Overlap: Shared features like protein misfolding,
mitochondrial issues, inflammation.
- SCI pain: Stem cell therapies gaining traction.
|
|
|
New
whitepaper: Modeling the genomic instability of Huntington’s disease
with iPSC technology
|
|
|
|
|
Axol Bioscience has developed iPSC lines from five HD
patients and one asymptomatic carrier. One of these, the CENSOi019-B
line (HTT: 14/125 CAG, now CAG143) contains an atypical allele that
displays instability in culture and is associated with accelerated
disease onset.
In our latest whitepaper, we explore how iPSC-derived
striatal neurons provide a scalable, physiologically relevant platform
for studying HD and evaluating potential therapeutics.
|
|
|
New eBook:
Human iPSC-derived cells and specialist services for Huntington’s
disease
|
|
|
|
|
Axol Bioscience offers iPSC-derived striatal neurons,
custom assays, and gene-editing support for advanced Huntington’s
disease modeling, helping researchers accelerate discovery with
physiologically relevant tools.
In our new eBook, you will learn how Axol Bioscience is
supporting HD research and drug development with iPSC-derived cell
models.
|
|
|
We’ll be at
the 36th International Symposium on ALS/MND
|
|
|
|
|
Join us next week to learn how our iPSC-derived motor
neuron disease model enables reliable, physiologically relevant ALS
research. We’ll present characterization data that demonstrates the
reproducibility of these models, an essential step toward building
robust, human-relevant systems for ALS drug discovery.
Sapna Vyas will present a poster titled: "Characterization of human
iPSC-derived motor neuron disease model for ALS drug discovery".
|
|
|
Planning your
last round of microglia experiments for 2025? Our cells are ready
|
|
|
|
|
We've spent the last 12 years developing the
manufacturing capabilities to become the first choice for high-quality,
functionally relevant iPSC-derived microglia to power models of
neurodegenerative diseases.
- Rapid maturation: Ready in 7 days
- Phenotypic relevance: Key markers (IBA-1, TMEM119, P2RY12)
- Functional relevance: Validated for phagocytosis, chemotaxis,
cytokine release
- Confidence: ISO 9001 & ISSCR compliant
|
|
|
Axol
Bioscience, coming to a conference near you
|
|
|
|
|
SLAS in winter, SOT and dermo-cosmetic events in spring,
MPS and BIO in summer, and it doesn't stop there! Come and see us if
you're attending the following conferences:
|
|
|
Better Human Disease Models
|
|
|
We use iPSCs to build more relevant models of human
disease to expand your understanding and de-risk drug development.
|
|
|
|
